216 related articles for article (PubMed ID: 22897212)
1. Off-label medication use.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Sep; 50(9):11-3. PubMed ID: 22897212
[TBL] [Abstract][Full Text] [Related]
2. Informed consent in off-label use and incapacitated persons.
Elger CE; Hoppe C
Epilepsia; 2009 Dec; 50 Suppl 12():79-80. PubMed ID: 19941536
[No Abstract] [Full Text] [Related]
3. Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethics.
Ruble J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):146-52. PubMed ID: 22764854
[TBL] [Abstract][Full Text] [Related]
4. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
5. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
6. Off-label psychotropic prescribing for young persons in medium security.
Haw C; Stubbs J
J Psychopharmacol; 2010 Oct; 24(10):1491-8. PubMed ID: 19423609
[TBL] [Abstract][Full Text] [Related]
7. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
[TBL] [Abstract][Full Text] [Related]
8. How physician obesity specialists use drugs to treat obesity.
Hendricks EJ; Rothman RB; Greenway FL
Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
[TBL] [Abstract][Full Text] [Related]
9. [Off-label prescribing].
Blondon K; Desmeules J; Vogt-Ferrier N; Besson M; Kondo-Oestreicher M; Dayer P
Rev Med Suisse; 2008 Jul; 4(165):1661-5. PubMed ID: 18767292
[TBL] [Abstract][Full Text] [Related]
10. Off-label and unlicensed prescribing in Europe: implications for patients' informed consent and liability.
Aagaard L; Kristensen K
Int J Clin Pharm; 2018 Jun; 40(3):509-512. PubMed ID: 29721740
[TBL] [Abstract][Full Text] [Related]
11. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
12. Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines.
Cohen SA; Lawson JA; Graudins LV; Pearson SA; Gazarian M
J Paediatr Child Health; 2012 Jun; 48(6):490-5. PubMed ID: 22050665
[TBL] [Abstract][Full Text] [Related]
13. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use.
Meadows WA; Hollowell BD
Int J Impot Res; 2008; 20(2):135-44. PubMed ID: 18004389
[TBL] [Abstract][Full Text] [Related]
14. Combination phentermine/topiramate for obesity treatment in primary care: a review.
Xiong GL; Gadde KM
Postgrad Med; 2014 Mar; 126(2):110-6. PubMed ID: 24685974
[TBL] [Abstract][Full Text] [Related]
15. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness.
Haw C; Stubbs J
J Intellect Disabil Res; 2005 Nov; 49(Pt 11):858-64. PubMed ID: 16207284
[TBL] [Abstract][Full Text] [Related]
16. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
17. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
Kmietowicz Z
BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
[No Abstract] [Full Text] [Related]
18. [Off-label use of drugs--the legal framework].
Koyuncu A
Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
[No Abstract] [Full Text] [Related]
19. Drug, patient, and physician characteristics associated with off-label prescribing in primary care.
Eguale T; Buckeridge DL; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
Arch Intern Med; 2012 May; 172(10):781-8. PubMed ID: 22507695
[TBL] [Abstract][Full Text] [Related]
20. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use.
Vox F; Capron AM; Kraus MF; Alexander GC; Kirschner KL
PM R; 2013 Oct; 5(10):882-9. PubMed ID: 24160301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
